



Clinical and Genetic Spectrums of Paediatric Cardiomyopathy in Hong Kong

SHI ZJ¹, CHAU FTJ², KWOK SY¹, YEUNG KS², FUNG LFJ²,
YUNG TC¹, CHUNG HYB², LUN KS¹

¹Department of Paediatric Cardiology, Queen Mary Hospital

² Department of Paediatrics and Adolescent Medicine, Li Ka Shing Faculty of
Medicine, The University of Hong Kong

Paediatric Cardiomyopathy



Rare (1 in 100,000)

Diagnostic challenge



Management dilemmas



Risk of sudden death

Exercise and schooling



Associated metabolic and neurological diseases

Reproductive decisions





Objectives

- To analyze the clinical and genetic characteristics of cardiomyopathy of Hong Kong children
- To identify the genotype-phenotype correlations in paediatric patients with cardiomyopathy

Objectives



Methods



<18 years old
Primary cardiomyopathies
(HCM, DCM, RCM, LVNC,
ARVC)
Follow up in QMH
paediatric cardiology clinic





Retrospective review of
clinical records



Analyze existing genetic results
(WES, gene panels or targeted testing)
by genetic analyst
Perform WES for untested patients
In accordance to **ACMG guidelines**¹
Cascade screening when indicated

**WES = whole exome sequencing*

WES Analysis Workflow



©American College of Medical Genetics and Genomics

ACMG PRACTICE RESOURCE | Genetics inMedicine

Corrected: Correction

Genetic evaluation of cardiomyopathy: a clinical practice resource of the American College of Medical Genetics and Genomics (ACMG)

Ray E. Hershberger, MD¹, Michael M. Givertz, MD², Carolyn Y Ho, MD³, Daniel P. Judge, MD⁴, Paul F. Kantor, MD⁵, Kim L. McBride, MD⁶, Ana Morales, MS, LGC¹, Matthew R. G. Taylor, MD⁷, Matteo Vatta, PhD^{8,9,10} and Stephanie M. Ware, MD, PhD^{9,11} on behalf of the ACMG Professional Practice and Guidelines Committee

Official journal of the American College of Medical Genetics and Genomics

SPECIAL ARTICLE | Genetics inMedicine

Open

Adaptation and validation of the ACMG/AMP variant classification framework for *MYH7*-associated inherited cardiomyopathies: recommendations by ClinGen's Inherited Cardiomyopathy Expert Panel

Results

Demographic and clinical characteristics

Clinical Characteristics	No of patients (N= 44)
Demographic features	
Age at latest follow-up (years)	9.8 ± 4.2
Gender (male/female)	29 (65.9%) / 15 (34.1%)
Median follow-up duration (range) (years)	7.2 (0.3 – 16.5)
Median age at initial presentation (range) (years)	0.3 (0.0 – 14.9)
Type of Cardiomyopathy	
Hypertrophic cardiomyopathy (HCM)	19 (43.2%)
Dilated cardiomyopathy (DCM)	20 (45.5%)
Restrictive cardiomyopathy (RCM)	2 (4.5%)
Left ventricular non-compaction (LVNC)	3 (6.8%)
Arrhythmogenic right ventricular cardiomyopathy (ARVC)	0

The Clinical Spectrum

Clinical Characteristics	No of patients (N= 44)
NYHA Class 3 or above	3 (6.8%)
History of arrhythmia	6 (13.6%)
Atrial tachyarrhythmia	3 (6.8%)
Ventricular tachyarrhythmia	3 (6.8%)
ICD/ CRT-D implantation	4 (9.1%)
Mechanical circulatory support	5 (11.4%)
Active	3 (6.8%)
Previous	2 (4.5%)
Listing for heart transplantation	4 (9.1%)
Received heart transplantation	2 (4.5%)

Findings of Genetic Evaluation

44 patients with cardiomyopathy

39 patients who received genetic evaluation
21 WES
11 Gene panel
7 Targeted gene testing

6 variants causing **isolated cardiomyopathy**

2 Pathogenic
4 Likely pathogenic


15 variants associated with **genetic syndromes**

9 Noonan Syndrome/ RASopathy
4 Metabolic disorders
2 Neuromuscular or neurodevelopmental disorders

18 classified as **negative**



6 VUS by ACMG guidelines
12 Negative

The Genetic Spectrum



Genotype-phenotype Correlations


	Gene Positive (n= 21)	Gene Negative (n= 18)	<i>p</i>
Male sex	13 (61.9%)	13 (72.2%)	0.73
Age at initial presentation (years)	2.1 ± 4.2	2.9 ± 4.2	0.53
Type of Cardiomyopathy	12 HCM 6 DCM 0 RCM 3 LVNC	6 HCM 10 DCM 2 RCM 0 LVNC	0.36
Syndromic/ extracardiac manifestations	11 (52.4%)	1 (5.6%)	0.002
NYHA class 3 or above	0	2 (11.1%)	0.21
History of Arrhythmia	1 (4.8%)	4 (22.2%)	0.16
ICD/ CRT-D implanted	1 (4.8%)	3 (16.7%)	0.32
Indicated for Device	1 (4.8%)	3 (16.7%)	0.32
Indicated for HTx	1 (4.8%)	3 (16.7%)	0.32




Key Findings

Diagnostic
Yield was
54%

Disease-causing variants identified in
QMH Paediatric Cardiomyopathy Cohort



Genetic Variants Associated with Paediatric Cardiomyopathy in Hong Kong




Rare or novel genetic variants that are not included in existing gene panels were identified


Table 3. Selected Genes in Association With Cardiomyopathy

Cardiomyopathy	Core Genes*	Estimates of Genetic Testing Diagnostic Yield	ACMG Secondary Findings Gene List	Metabolic Causes of Cardiomyopathy	Examples of Genetic Syndromes
HCM	<i>MYH7, MYBPC3, TNNT2, TNNC1, TNNT3, TPM1, MYL2, MYL3, ACTC1, ACTN2, CSRP3, PLN, TTR, PRKAG2, LAMP2, GLA</i>	30%–60%	<i>MYBPC3, MYH7, TNNT2, TNNT3, TPM1, MYL3, ACTC1, PRKAG2, GLA, MYL2, LMNA</i>	<i>GAA</i> (Pompe); Mitochondrial disease genes	RASopathies (eg, Noonan syndrome, others); Friedreich ataxia
DCM	<i>TIN1, LMNA, MYH7, TNNT2, BAG3, RBM20, TNNC1, TNNT3, TPM1, SCNSA, PLN</i> . For testing, all HCM and ARVC genes are recommended to be included.	10%–40%		Mitochondrial disease genes	Muscular dystrophies; Alström syndrome
ARVC	<i>DES, DSC2, DSG2, DSP, JUP, LMNA, PKP2, PLN, RYR2, SCNSA, TMEM43, TIN1</i> ; consider full DCM panel	10%–50%	<i>PKP2, DSP, DSC2, TMEM43, DSG2, RYR2, SCNSA</i>		Naxos syndrome; Carvajal syndrome
RCM	Consider HCM or DCM gene panel	10%–60%			
LVNC	Use the gene panel for the cardiomyopathy identified in association with the LVNC phenotype	Unknown		Mitochondrial disease genes, including <i>TAZ</i> in Barth syndrome	1p36 deletion syndrome; RASopathies

Recommended Gene Selection according to HFSA 2018 guideline



Am Fam Physician. 2014 Jan



**Presence of syndromic/
extracardiac manifestations
were associated with
positive genetic findings**

Take Home Messages



Genetic testing is recommended for paediatric patients with cardiomyopathy



Although gene panels are still the mainstay of genetic testing , whole exome sequence is powerful to identify rare or novel variants in special circumstances



Patients with syndromic/ extracardiac manifestations are more likely to have an identified genetic variant

References

1. Hershberger, Ray E., et al. “Genetic Evaluation of Cardiomyopathy: a Clinical Practice Resource of the American College of Medical Genetics and Genomics (ACMG).” *Genetics in Medicine*, vol. 20, no. 9, 2018, pp. 899–909.
2. Wilkinson, James D., et al. “The Pediatric Cardiomyopathy Registry and Heart Failure: Key Results from the First 15 Years.” *Heart Failure Clinics*, vol. 6, no. 4, 2010, pp. 401–413.



Thank You

Dr. Julia Shi
Resident
Department of Paediatric Cardiology
Queen Mary Hospital
Hong Kong SAR
Email: sz589@ha.org.hk